Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9596 posts found.

afinitor_combo-front

Novartis drug Afinitor significantly reduces seizures in TSC patients

April 21, 2016 Research and Development Afinitor, Novartis, Tuberous Sclerosis Complex, drug, seizure, seizures, tsc

Novartis (SIX: NOVN) has announced the results from a Phase III clinical trial which shows that Afinitor (everolimus) significantly reduced …
News
clinicaltrial1

BioMarin announces positive data from early stage trials of haemophilia A gene therapy

April 21, 2016 Research and Development BioMarin Pharmaceutical, Phase II, drug trial, haemophilia A gene therapy

BioMarin Pharmaceutical (Nasdaq: BMRN) said early-stage trials for its haemophilia A gene therapy showed encouraging data. Chief Medical Officer, Hank …
News
amgen_flag

Amgen’s drug reduces rates of bleeding in rare childhood disorder

April 21, 2016 Research and Development, Sales and Marketing Amgen, blood disorder, children, nplate, paediatric, platelet, rare, romisplostim

Amgen (NASDAQ: AMGN) has announced the results of a Phase III trial, published in The Lancet, which shows that Nplate …
News
abbvie_0

Abbvie acquires immune-oncology target from argenx

April 21, 2016 Research and Development, Sales and Marketing AbbVie, Protein, argenx, garp, immuno-oncology, immunosuppresive

AbbVie (NYSE:ABBV) has announced the acquisition of a new preclinical-stage human antibody program evaluating the novel immune-oncology target GARP, a …
News

Illumina shares plunge as it cuts Q1 outlook

April 20, 2016 Research and Development, Sales and Marketing Financial, Illumina, Share price, Shares, outlook, revenue, stock market

Shares in Illumina (Nasdaq: ILMN) plunged after the company cut its revenue estimates for the first quarter based on low …
News
opdivo_1_1

Focus: Bristol-Myers Squibb’s wonder drug – Opdivo

April 20, 2016 Research and Development, Sales and Marketing BMS, growth, immuno-oncology, opdivo, sales

By Anjali ShuklaNew data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat head and neck cancer showed superior survival compared with …
Feature
jardiance-web

Lilly and Boehringer Ingelheim to evaluate diabetes drug for treatment of heart failure

April 20, 2016 Research and Development Boehringer Ingelheim, Eli Lilly, cardiovascular death, diabetes, heart attack, jardiance, lilly

Eli Lilly (NYSE: LLY) and Boehringer Ingelheim have announced plans to conduct two outcome trials evaluating diabetes medicine Jardiance (empagliflozin) …
News
bi_microparts_image

Boehringer Ingelheim posts 11% rise in FY15 sales boosted by diabetes business

April 20, 2016 Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, FY, earnings, forecasts, outlook, results

Boehringer Ingelheim reported 11% jump in sales for 2015 driven by its diabetes business and said for 2016 it sees …
News
gilead-sciences

Gilead presents data highlighting progress and efficacy in liver and hepatitis C therapies

April 20, 2016 Research and Development, Sales and Marketing Gilead, harvoni, hepatitis, liver, sofosbuvir

Gilead (NASDAQ: GILD) has presented a broad range of results on its current and potential therapeutics at the International Liver …
News
jj_sign_on_wall

J&J raises FY outlook, Q1 beats estimates

April 20, 2016 Business Services, Research and Development, Sales and Marketing Financial, Johnson & Johnson, Q1, earnings, results, revenue, sales

Healthcare giant Johnson & Johnson (NYSE: JNJ) raised its full-year outlook and posted first-quarter earnings ahead of estimates despite currency headwinds. …
News
whats_up_doc

Lemtrada shows clinical efficacy in multiple sclerosis in 10-year follow-up data

April 20, 2016 Research and Development, Sales and Marketing Lemtrada, Sanofi, alemtuzumab, multiple sclerosis, sanofi genzyme

Sanofi Genzyme has presented 10-year follow-up data on Lemtrada (alemtuzumab) which points to its efficacy in patients with relapsing-remitting multiple …
News

Bayer says its Xarelto shows lower risk of stroke, brain haemorrhage for irregular heart rhythm condition vs BMS’ Coumadin

April 19, 2016 Manufacturing and Production, Research and Development Bayer, Bristol-Myers Squibb, anti blood-clot, drug trial

New trials for anti blood-clotting drug Xarelto (rivaroxaban) showed lower risk of stroke and haemorrhage in patients with irregular heart …
News
bms_building_uk

Bristol-Myers Squibb’s Opdivo shows positive results in early stage trials for advanced skin cancer

April 19, 2016 Manufacturing and Production, Research and Development Bristol-Myers Squibb, drug trial, immuno-therapy, oncology, opdivo

New data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat advanced melanoma showed overall survival of five years in 34% patients, …
News
opdivo_1

Opdivo shows biggest survival increase for head and neck cancer in 20 years in Phase III trials

April 19, 2016 Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, blockbuster, head and neck cancer, nivolumab, oncology, opdivo, potential, squamous

Opdivo (nivolumab) showed the biggest increase in survival for patients with head and neck cancer for 20 years, according to …
News
eli_lilly_logo

Eli Lilly drops development of diabetes drug in Phase III

April 19, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, Transition Therapeutics, diabetes, drug trial

US drugmaker Eli Lilly (NYSE: LLY) has pulled out of the partnership with Transition Therapeutics (TSX: TTH) to develop its …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026